AptarGroup is poised for growth in its Pharma and Closure segments, but challenges are expected in the Beauty segment. The prescription drug business is expected to drive revenue growth in the Pharma segment. Margin expansion anticipated from operational leverage, cost management, and premium product mix.
AptarGroup, Inc. (NYSE:ATR ) Q4 2024 Earnings Conference Call February 7, 2025 9:00 AM ET Company Participants Mary Skafidas - Senior Vice President, Investor Relations & Communications Stephan Tanda - President & Chief Executive Officer Vanessa Kanu - Executive Vice President & Chief Financial Officer Conference Call Participants George Staphos - Bank of America Ghansham Panjabi - Baird Matt R...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2025 Quarterly Conference Call Dates.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.